Financial Results and Information | CSL Limited
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
investors.csl.comHere’s the latest you can use right now on CSL share price declines.
If you’d like, I can pull the most up-to-date numbers and compile a short watchlist (current price, intraday high/low, latest broker notes) and create a quick chart showing CSL’s price trend over the last 12–18 months. I can also summarize what recent guidance and strategic moves (like the Seqirus demerger) imply for near-term price action. Please tell me which format you prefer (brief bullet summary, table, or chart).
Citations:
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
investors.csl.comCSL shares recover slightly after hitting an 8-year low as analysts highlight a potential upside from current levels.
www.fool.com.auCSL, one of Australia's largest stocks by market value, plunged on resuming trade after two days on announcing a discounted $5 billion placement to fund the $11.7 billion acquisition of Swiss drugmaker Vifor Pharma.
economictimes.indiatimes.comCSL shares (ASX: CSL) extended a brutal 12-month selloff, briefly touching A$122.48 before closing higher at A$124.41 on Tuesday, with the price touching it's lowest price levels since 2017 and capping a 50% decline that has stunned long-term holders of what was once Australia's most reliable healthcare compounder. In a potentially interesting twist, the latest
thebull.com.auThe ASX closed lower as CSL plunged after a profit downgrade, while rising Middle East tensions pressured investor sentiment.
azzet.comAll the latest CSL (ASX:CSL) share price movements, news, expert commentary and investing advice from The Motley Fool Australia.
www.fool.com.auCSL shares (ASX:CSL) struck a fresh multi-year low at A$125.78, capping a 49.91% decline over twelve months as repeated guidance cuts and margin pressures continue to erode confidence in what was once Australia's most valuable healthcare stock. The CSL share price closed at their lowest level in nearly 10 years, extending a relentless stair-step decline
thebull.com.auCSL, one of Australia's largest stocks by market value, plunged on resuming trade after two days on announcing a discounted $5 billion placement to fund the $11.7 billion acquisition of Swiss drugmaker Vifor Pharma.
economictimes.indiatimes.com